Bladder Cancer Markers, Urine

Bladder Cancer Markers, Urine is a topic covered in the Davis's Lab & Diagnostic Tests.

To view the entire topic, please or .

Nursing Central is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:

-- The first section of this topic is shown below --

Synonym/Acronym:
Nuclear matrix protein (NMP) 22, bladder tumor antigen (BTA), cytogenic marker for bladder cancer.

Rationale
Bladder cancer markers can identify undiagnosed bladder cancer; however, these noninvasive markers are mainly used to assist in diagnosing residual or recurring bladder cancer; cystoscopy is still considered the gold standard for detection of bladder cancer.

Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction. As appropriate, provide the required urine collection container and specimen collection instructions.

Normal Findings
Method: Enzyme immunoassay for NMP22 and BTA, fluorescence in situ hybridization (FISH) for cytogenic marker. Care must be taken to use the same assay method if serial measurements are to be taken.

NMP22: Negative: Less than 6 units/mL, borderline: 6 to 10 units/mL, positive: greater than 10 units/mL.

BTA: Negative.

Cytogenic Marker: Negative.

Critical Findings and Potential Interventions

  • Bladder cancer

Timely notification to the requesting health-care provider (HCP) of any critical findings and related symptoms is a role expectation of the professional nurse. A listing of these findings varies among facilities.

-- To view the remaining sections of this topic, please or --

Synonym/Acronym:
Nuclear matrix protein (NMP) 22, bladder tumor antigen (BTA), cytogenic marker for bladder cancer.

Rationale
Bladder cancer markers can identify undiagnosed bladder cancer; however, these noninvasive markers are mainly used to assist in diagnosing residual or recurring bladder cancer; cystoscopy is still considered the gold standard for detection of bladder cancer.

Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction. As appropriate, provide the required urine collection container and specimen collection instructions.

Normal Findings
Method: Enzyme immunoassay for NMP22 and BTA, fluorescence in situ hybridization (FISH) for cytogenic marker. Care must be taken to use the same assay method if serial measurements are to be taken.

NMP22: Negative: Less than 6 units/mL, borderline: 6 to 10 units/mL, positive: greater than 10 units/mL.

BTA: Negative.

Cytogenic Marker: Negative.

Critical Findings and Potential Interventions

  • Bladder cancer

Timely notification to the requesting health-care provider (HCP) of any critical findings and related symptoms is a role expectation of the professional nurse. A listing of these findings varies among facilities.

There's more to see -- the rest of this entry is available only to subscribers.